Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 4/20 | 0.47 |
| ▸ | PYGL | P06737 | 6/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27367147 | 0.86 | SIGMAR1 (0.48) | CHRM1SIGMAR1CCR5OPRK1KMT2A | |
| SCHEMBL27529191 | 0.85 | SIGMAR1 (0.47) | CHRM1SIGMAR1CCR5OPRK1KMT2A | |
| SCHEMBL27553023 | 0.85 | SIGMAR1 (0.47) | CHRM1SIGMAR1CCR5OPRK1KMT2A | |
| SCHEMBL27366400 | 0.83 | MTNR1A (0.57) | — | |
| SCHEMBL5236753 | 0.77 | MEN1 (0.47) | KMT2AMEN1 | |
| SCHEMBL27366117 | 0.75 | HTR2A (0.54) | OPRK1NPC1RAB9A | |
| SCHEMBL31332133 | 0.75 | TDP1 (0.64) | CHRM1KMT2AMEN1 | |
| SCHEMBL3581821 | 0.75 | TDP1 (0.64) | CHRM1KMT2AMEN1 | |
| SCHEMBL2405208 | 0.74 | SIGMAR1 (0.60) | CHRM1SIGMAR1CCR5PYGLOPRK1 | |
| SCHEMBL9711167 | 0.74 | MEN1 (0.47) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | CHRM1 870/4885SIGMAR1 623/4885CCR5 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.